You can now read 5 articles in a month for free on Read as much as you want anywhere and anytime for just 99¢.

Around the Region

Alnylam acquires a Merck unit

Alnylam Pharmaceuticals Inc., a Cambridge company specializing in RNA interference therapies designed to silence genes that cause diseases, said it has acquired a Merck subsidiary called Sirna Therapeutics, which also works on RNA technologies, for $175 million.

The acquisition of Merck’s RNAi intellectual property will advance Alnylam’s plans to develop a new class of medicines, Alnylam said.

Continue reading below

Under the agreement, Alnylam will make an upfront payment of $25 million in cash and $150 million in common stock to Merck.

Merck is also eligible to receive up to $105 million in developmental and sales milestone payments per product, as well as single-digit royalties, associated with the progress of certain pre-clinical candidates discovered by Merck.

Merck is also eligible to receive up to $10 million in milestone payments and single-digit royalties on Alnylam products covered by Sirna Therapeutics’ patent estate.

Chris Reidy can be reached at
Loading comments...

Wake up with today's top stories.

Want each day's news headlines delivered fresh to your
inbox every morning? Just connect with us
in one of the following ways:
Please enter a valid email will never post anything without asking.
Privacy Policy
Subscriber Log In

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of